Geisinger’s five-year collaboration with Regeneron Pharmaceuticals will include one of the largest U.S. populations of participants for a study of this kind. Geisinger plans to collect samples from more than 100,000 consented patient volunteers. Regeneron’s genetics center and its researchers will then perform sequencing and genotyping on the samples.
David H. Ledbetter, PhD, Geisinger’s executive vice president and chief scientific officer, said the collaboration has the potential to provide Geisinger with tools to improve its ability to foresee diseases before the onset of symptoms and diagnose chronic and potentially fatal conditions before it’s too late to intervene.
“Research is a core part of Geisinger’s mission, and there is no more important medical research being done today than in genomics,” Geisinger Health President and CEO Glenn D. Steele Jr., MD, PhD, said in the release. “The combination of Geisinger and Regeneron brings together a unique set of assets and expertise that allow us to conduct research of this size and scope. I believe the long term benefits to human health and patient care will be tremendous.”
More Articles on Hospitals and Collaborations:
FDA Orders 23andMe to Stop Sale of Personal Genome Service
Personalized Medicine: How It Will Change How Physicians Prescribe, Drug Companies Develop, and Health Systems Thrive
New York Genome Center Opens Doors
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
